

FACSIMILE TRANSMITTAL

ROBINS & PASTERNAK LLP
1731 Embarcadero Road, Suite 230
Palo Alto, CA 94303
Telephone: (650) 493-3400
Facsimile Number: (650) 493-3440

Date: August ~~26~~, 2003
To: Examiner L. A. Clow
United States Patent and Trademark Office
Facsimile No. 1-703-308-4242
From: Roberta L. Robins, Reg. No. 33,208
Re: 08/844,215
Message: **PLEASE MAKE ATTACHED SUPPLEMENTAL
AMENDMENT OF OFFICIAL RECORD.**

Total number of pages, including this cover sheet: 17

WARNING: This facsimile message and accompanying documents are intended only for the use of the addressee indicated above. Information that is privileged or otherwise confidential may be contained therein. If you are not the intended recipient, you are hereby notified that any dissemination, copying, review or use of the above message or the accompanying documents is strictly prohibited. If you have received this message in error, please notify us immediately by telephone or facsimile, and mail the original to us at the above address. Thank you.


Please contact us at (650) 493-3400 if you have any problems receiving this transmission.

Atty Dkt No. PL08146.107
2300-6146.20
USSN: 08/844,215
PATENT

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office at 1 703-308-4242 on

8/26/03

Date


Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

PERSSON et al.

Serial No.: 08/844,215

Art Unit: 1631

Filing Date: April 17, 1997

Examiner: L. A. Clow

Title: HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR
HEPATITIS C VIRUS (HCV) E2 ANTIGEN

AMENDMENT TRANSMITTAL LETTER

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing is a Supplemental Amendment in the
above patent application in response to the Advisory Action of June 20, 2003.

☒ Applicants request an extension of time for 2 months from July 12,
2003 to September 12, 2003 . Please charge Deposit Account No.
18-1648 the \$410 fee.

☐ No additional fee is required.

☒ Also enclosed: Return Postcard

FAX RECEIVED
1 703-308-4242
GROUP 1600

FAX RECEIVED
AUG 26 2003
GROUP 1600

Atty Dkt No. PL08146.107
 2300-6146.20
 USSN: 08/844,215
 PATENT

No. of Claims After Amendment	Most Claims Previously Paid			Extra Claims			Additional Fee		
A. Total Claims	76	-	116	=	0	x	\$18	-	\$0
B. Ind. Claims	5	-	5	=	0	x	\$84	=	
C. If amended to contain multiple dependent claims, add 280							\$280	-	\$0
D. Total Amendment Fee (Total of A, B & C)								=	
E. If small entity, 50% reduction of Total Amendment Fee (50% of D)								=	
F. Total Amendment Fee (D minus E)								=	\$0.00

A check for \$ * to cover the extension of time fee and extra claims fee is attached.

X Charge \$410.00 to Deposit Account No. 18-1648.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: 8/25/03

By: 


Roberta L. Robins
 Registration No. 33,208
 Attorney for Applicants

Chiron Corporation
 Intellectual Property - R440
 PO Box 8097
 Emeryville, CA 94662-8097
 Telephone: 650-493-3400
 Facsimile: 650-493-3440

Atty Dkt No: PL08146.107
2302-6146.20
PATENT

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office at 1-703-308-4242 on 8/26/03.

8/26/03
Date


Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

PERSSON et al.

Serial No.: 08/844,215

Art Unit: 1631

Filing Date: April 17, 1997

Examiner: L. A. Clow

Title: HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR HEPATITIS C
VIRUS (HCV) E2 ANTIGEN

SUPPLEMENTAL AMENDMENT

Box AF
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

This Supplemental Amendment addresses issues presented in the Advisory Action mailed June 20, 2003. Applicants thank Examiner Clow and Examiner Zeman for agreeing to consider this Amendment. Reconsideration of the application in view of the following amendments and remarks is respectfully requested.